Evidence map›Paper›PMID 42516437›Full record

ArticleFrontiers in cellular and infection microbiology2026

Unveiling the anti-inflammatory power of star anise-cinnamon compound essential oil against MDR

Ziheng Xu, Jie Zhang, Rongdian Lin, Zuxiang Luan, Kai Shao, Yanhua Chen, Jie Liang, Chuangrong Huang, Dapei Zhang, Junyu Tao and 5 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ziheng Xu *Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Jie Zhang *Guangxi Key Laboratory of Translational Medicine for Treating High-incidence Infectious with Integrative Medicine, Guangxi University of Chinese Medicine, Nanning, China.
Rongdian Lin *Postdoctoral Innovation Base of Southern Medical University, Guangdong Luofushan Tranditional Medicine Co., LTD., Huizhou, China.
Zuxiang Luan *Student Employment Center, Nanning Normal University, Nanning, China.
Kai ShaoSchool of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, China.
Yanhua ChenSchool of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, China.
Jie LiangSchool of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, China.
Chuangrong HuangSchool of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, China.
Dapei ZhangSchool of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, China.
Junyu TaoGuangxi Key Laboratory of Translational Medicine for Treating High-incidence Infectious with Integrative Medicine, Guangxi University of Chinese Medicine, Nanning, China.
Haibo TangGuangxi Key Laboratory of Translational Medicine for Treating High-incidence Infectious with Integrative Medicine, Guangxi University of Chinese Medicine, Nanning, China.
Weizhong HuangPostdoctoral Innovation Base of Southern Medical University, Guangdong Luofushan Tranditional Medicine Co., LTD., Huizhou, China.
Longjian HuangHeadmaster's Office, Youjiang Medical University for Nationalities, Baise, China.
Hai LiSchool of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, China.
Dingqiang ChenZhujiang Hospital of Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aimed to investigate the antiinfi ammatory effects and potential molecular mechanisms of star anise-cinnamon compound essential oil (SCEO) against multidrug-resistant Salmonella Thompson (MDR S. Thompson) infection in mice. Methods: An intestinal infection model was established in mice by oral gavage of MDR S. Thompson (1×109 CFU/mL) for two consecutive days. Experimental animals were randomly assigned to a blank group, a model group, a levofioxacin group (positive control), and SCEO low-, medium-, and high-dose groups (100, 200, and 400mg/kg, respectively). Results and Discussion: SCEO intervention significantly alleviated clinical symptoms in infected mice, restored pathological damage in the liver and ileum, and normalized the liver index. Gas chromatography-mass spectrom- etry (GC-MS) analysis identified trans-cinnamaldehyde and trans-anethole as the primary active components of SCEO. Network pharmacology and molecular docking analyses revealed strong binding affinities between these components and Toll-like receptor 4 (TLR4), RELA, and mitogen-activated protein kinase 14 (MAPK14) (Vina score < -5.0 kcal/mol). Further in vivo and in vitro experiments demonstrated that SCEO significantly downregulated the mRNA expression of key cytokines, including Tlr4, interleukin-6 (Il6), tumor necrosis factor (Tnf), and interleukin-17A (Il17a), and suppressed the overactivation of the TLR4/nuclear factor kappa-B (NFĸB)/MAPK signaling pathway. SCEO effectively alleviated Salmonella-induced infiammatory damage, a protective process potentially me- diated through the modulation of the TLR4/NFĸB/MAPK signaling axis. These findings provide a theoretical basis for the development of SCEO as a natural, plant-derived anti-infective agent.

Indexed as

Anti-Bacterial AgentsAnti-Inflammatory AgentsCinnamomum zeylanicumDrug Resistance, Multiple, BacterialOils, VolatileSalmonellaSalmonella InfectionsAcroleinAnimalsCytokinesDisease Models, AnimalGas Chromatography-Mass SpectrometryIleumLiverMiceMolecular Docking SimulationAcroleinAnti-Bacterial AgentsAnti-Inflammatory AgentscinnamaldehydeCytokinesNF-kappa BOils, VolatileRela protein, mouseTlr4 protein, mouseToll-Like Receptor 4Transcription Factor RelAcinnamonessential oilmultidrug resistancenetwork pharmacology and molecular dockingSalmonella Thompsonstar aniseTLR4/NF-κB inflammatory pathway

Identifiers

PMID42516437
PMCPMC13403108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.